# US 2017/0283536 A1 · Polymer particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283536 A1
- Document ID: US20170283536A1
- Status: Published application
- Kind: A1
- Application number: 15/630,048
- Filed: 2017-06-22
- Published: 2017-10-05
- Earliest claimed: 2013-09-19
- Assignees: Terumo Kabushiki Kaisha
- Applicants: Terumo Corporation
- Inventors: Gregory M. Cruise; Gloria Hincapie; Clayton Harris
- Web page: https://patentgrep.com/patent/US20170283536A1

## CPC

- A61L 24/001: {Use of materials characterised by their function or physical properties}
- A61K 9/0029: {Parenteral nutrition; Parenteral nutrition compositions as drug carriers}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61L 24/06: obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)}
- A61L 31/048: {obtained by reactions only involving carbon-to-carbon unsaturated bonds (A61L31/041 takes precedence)}
- C08F 220/38: Esters containing sulfur
- C08F 220/382: {and containing oxygen, e.g. 2-sulfoethyl (meth)acrylate}
- C08F 220/56: Acrylamide; Methacrylamide
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices
- C08F 222/1006: {of polyhydric alcohols or polyhydric phenols}
- C08F 222/102: {of dialcohols, e.g. ethylene glycol di(meth)acrylate or 1,4-butanediol dimethacrylate}
- C08F 222/385: {Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide}
- C08F 222/408: {substituted imides comprising other heteroatoms}
- C08L 33/02: Homopolymers or copolymers of acids; Metal or ammonium salts thereof
- C08L 33/14: of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
- C08L 33/26: Homopolymers or copolymers of acrylamide or methacrylamide
- C08L 2203/02: for biomedical use
- C08L 2312/00: Crosslinking
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

## Claims

### Claim 1

An embolic system including:
a delivery device; and
an embolic solution including polymer particles, wherein the polymer particles include:
an acrylate, acrylamide, methacrylamide, methyl methacrylate, or a combination thereof, and
a crosslinker,
wherein the polymer particles have a spherical diameter between about 40 μm and about 1,200 μm.

### Claim 2 (depends on 1)

The embolic system of claim 1, wherein the polymer particles are susceptible to degradation through hydrolysis or enzymatic action, and wherein the degradation provides less than about 10% of the polymer particles intact after about 5 days.

### Claim 3 (depends on 1)

The embolic system of claim 1, wherein the spherical diameter is between about 75 μm and about 1,200 μm.

### Claim 4 (depends on 1)

The embolic system of claim 1, wherein the crosslinker includes at least two functional groups.

### Claim 5 (depends on 1)

The embolic system of claim 1, wherein the crosslinker includes at least one linkage susceptible to degradation through hydrolysis or enzymatic action.

### Claim 6 (depends on 1)

The embolic system of claim 1, wherein the crosslinker is bis-glycidyl amino alcohol,
wherein a, b, c, d, e, and f are each independently 1-20.

### Claim 7 (depends on 5)

The embolic system of claim 5, wherein the at least one linkage is an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, a peptide cleavable by matrix cathepsins, or a combination thereof.

### Claim 8 (depends on 1)

The embolic system of claim 1, including a second crosslinker including a second linkage selected from an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, and a peptide cleavable by matrix cathepsins.

### Claim 9 (depends on 1)

The embolic system of claim 1, wherein the crosslinker is bis-glycidyl amino alcohol or bi-functionalized methacryloyl-Ala-Pro-Gly-Leu-AEE-methacrylate.

### Claim 10 (depends on 1)

The embolic system of claim 1, wherein the delivery device is a catheter.

### Claim 11 (depends on 1)

The embolic system of claim 1, wherein the delivery device is a microcatheter.

### Claim 12 (depends on 1)

The embolic system of claim 1, wherein the delivery device is a needle.

### Claim 13 (depends on 1)

The embolic system of claim 1, wherein the delivery device and the embolic solution are sterilized.

### Claim 14 (depends on 1)

The embolic system of claim 1, wherein the embolic solution includes a monomer including an ionizable functional group.

### Claim 15 (depends on 14)

The embolic system of claim 14, wherein the ionizable functional group is basic or acidic.

### Claim 16 (depends on 1)

The embolic system of claim 1, wherein the embolic solution includes a radiopaque contrast agent.

### Claim 17 (depends on 1)

The embolic system of claim 1, wherein the embolic solution includes a dye.

### Claim 18 (depends on 1)

The embolic system of claim 1, wherein the embolic solution is provided in a vial.

### Claim 19 (depends on 1)

The embolic system of claim 1, wherein the embolic solution is provided in a syringe.

### Claim 20 (depends on 1)

The embolic system of claim 1, wherein the polymer particles have a circularity greater than about 0.9.